← Leaderboards
Jingchuan Guo
University Of Florida
$1,978,842
Attributed
$4,548,274
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$4,548,274 · 3
By mechanism
R01$4,252,350 · 2
R43$295,924 · 1
Top collaborators
- Hui Shao5 shared
- Jiang Bian3 shared
- Ramzi George Salloum2 shared
- Lixia Yao1 shared
Most similar at University Of Florida
Same institution · by research overlap
- Yi Guo$3,756,653
- Hui Shao$4,879,138
- Caitrin W McDonough$1,019,914
- Tezcan Ozrazgat Baslanti$579,876
- Elizabeth A Shenkman$13,048,879
Others in their field
Other Rising Stars on “Electronic Health Record”
- Gary Mays · Axle Informatics, Llc$59,047,077
- Cathie Snyder · Rho Federal Systems Division, Inc.$13,836,971
- Christopher J. Lindsell · Vanderbilt University Medical Center$10,402,454
- Michael Hogarth · University Of California, San Diego$10,285,272
- Suma Babu · Massachusetts General Hospital$9,819,674
- Sabrina Paganoni · Massachusetts General Hospital$9,819,674
Research focus
Electronic Health RecordAlzheimer&AposCaringMachine LearningInnovationClinical CareSocial Health DeterminantsMedicalDesignSocialQuality Of CareProgramsHealth EquityPublic HealthClinical ResearchMachine Learning AlgorithmPatient OrientedPersonsRecommendationLinkAmericanElectronic Health Record SystemEquityDisparity
Grant awards (8)
iSMART: intelligent Social risk Management in AD/ADRD paTients$722,946
R01 · FY2025 · AG · contact PI
Building Equity Improvement into Quality Improvement in the use of New Glucose-lowering Drugs (GLDs) through Individualized Drug Value Assessment in People with Diabetes$593,453
R01 · FY2025 · DK · contact PI
iSMART: intelligent Social risk Management in AD/ADRD paTients$752,903
R01 · FY2024 · AG · contact PI
Building Equity Improvement into Quality Improvement in the use of New Glucose-lowering Drugs (GLDs) through Individualized Drug Value Assessment in People with Diabetes$596,806
R01 · FY2024 · DK · contact PI
Addressing Social Determinants of Health in Systemic Lupus Erythematosus$295,924
R43 · FY2024 · MD
Building Equity Improvement into Quality Improvement in the use of New Glucose-lowering Drugs (GLDs) through Individualized Drug Value Assessment in People with Diabetes$631,513
R01 · FY2023 · DK · contact PI
Supplement of NIDDK R01 newer GLDs and Clinical Outcomes$290,798
R01 · FY2023 · DK · contact PI
Building Equity Improvement into Quality Improvement in the use of New Glucose-lowering Drugs (GLDs) through Individualized Drug Value Assessment in People with Diabetes$663,931
R01 · FY2022 · DK · contact PI